New England Journal of Medicine · 2013 · 332 citations · 49 references
MedicineImmunologyPharmacotherapyImmunopathologyInflammationRheumatologyAnti-inflammatory PharmacologyCrohn Disease PharmacotherapyGastrointestinal InflammationImmune-mediated Inflammatory DiseasesInflammatory Bowel DiseaseInflammatory Disease PharmacotherapyInflammatory Bowel Disease PathophysiologyInflammatory Bowel Disease TherapyTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor Therapy
A 35-year-old man presents with an exacerbation of Crohn's disease. Treatment with a TNF inhibitor is recommended. TNF inhibitors block the effects of the proinflammatory cytokine TNF-α, and several have been shown to be effective in treating inflammatory bowel disease.
49
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text